TSO3 files supporting documentation for exporting its STERIZONE 125L+ Sterilizer to the U.S. and Europe

TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that it has filed supporting technical documentation to the US Regulatory Agency and to the European Notified Body, in order to obtain clearance to export the STERIZONE(R) 125L+ Sterilizer to these markets.

The Company announced receiving Health Canada authorization to market this sterilizer in Canada on December 17, 2009. In Canada the new STERIZONE(R) 125L+ Sterilizer offers three cycles in a single sterilizer and is able to meet healthcare sterilization demands for terminal sterilization that previously required two or more low temperature sterilization systems. Engineered like other TSO3 products to be customer safe and eco-friendly, this new low temperature sterilization system also offers increased speed and instrument compatibility, high throughput and cost effective sterilization.

"We are extremely pleased that we have met the milestones of regulatory submission in multiple markets that we set out for ourselves and communicated to our investors during the year", stated Mr. R.M. (Ric) Rumble, President and CEO of TSO3. "Our new total solution in sterilization comes at a time when customers are seeking alternatives for their low temperature sterilization needs", concluded Mr. Rumble.

On December 16, 2009, TSO3 announced having entered into a global partnership with 3M, for the exclusive supply and distribution of the STERIZONE(R) 125L+ Sterilizer through 3M's operations worldwide as regulatory clearances are achieved.

Source: TSO3 INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
The neutralizing antibody response in mRNA vaccinated and boosted healthcare workers against major circulating SARS-CoV-2 Omicron subvariants